OREANDA-NEWSThe pharmaceutical company Stada has entered into a deal to acquire a portfolio of branded products from Takeda Pharmaceutical for $ 660 million, the Stada said in a statement. Under the terms of the transaction, a portfolio of 20 OTC and prescription products registered in Russia, Georgia, Armenia, Azerbaijan, Belarus, Kazakhstan, Uzbekistan and other countries will be transferred to the Stada group. As noted, the deal included drugs for the treatment of diabetes, cardiovascular and respiratory diseases, as well as dietary supplements. The transaction is expected to close in the first quarter of 2020. 

“Today it's the largest acquisition in the history of Stada that will allow us to become one of the key players in a large and dynamically developing market. Products under the Stada brand are already represented in most of the most popular categories of pharmacy demand. However, we continue to expand the portfolio of brand generics, strengthening positions in strategically important niches for us and developing new directions", the words of Stada CEO Peter Goldschmidt are quoted in the message.